AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Depression Drugs Market & Industry Outlook, 2019-2024 - ResearchAndMarkets.com

November 18, 2019

DUBLIN--(BUSINESS WIRE)--Nov 18, 2019--

The “Depression Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024” report has been added to ResearchAndMarkets.com’s offering.

The global depression drugs market is expected to grow at a CAGR of 2.5% during 2019-2024.

The growing prevalence of major depressive disorders across the globe is the key factor driving the growth of the market. Depression in adolescents and adults is increasing due to several factors including social isolation, improper dietary habits and work-life imbalance. Furthermore, the increasing geriatric population across the globe that suffers from isolation from family and friends, along with other health-related issues, are also augmenting the growth of the market.

However, there is rising awareness about depression as a psychological issue and methodologies to cure it, which has enhanced the adoption of these drugs among patients of all age groups. Additionally, the emergence of novel techniques for the development of antidepressants with minimal side-effects and prolonged results, along with the acceptance of new medications, is also favoring the market growth. For instance, psychedelics such as ketamine are widely considered to ease the symptoms of depression and provide relief.

Competitive Landscape

The report has also analyzed the competitive landscape of the market with some of the key players being Otsuka Pharmaceutical, Pfizer, Eli Lilly and Company, AstraZeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical Company, Allergan, Johnson & Johnson, Zhejiang NHU Company Ltd, Sebela Pharmaceuticals, etc.

Key Questions Answered in This Report

Key Topics Covered

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Key Industry Trends

5 Global Depression Drugs Market

5.1 Market Overview

5.2 Market Performance

5.3 Market Breakup by Drug Class

5.4 Market Breakup by Disorder Type

5.5 Market Breakup by Drug Type

5.6 Market Breakup by Distribution Channel

5.7 Market Breakup by Region

5.8 Market Forecast

6 Market Breakup by Drug Class

6.1 Atypical Antipsychotics

6.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

6.3 Selective Serotonin Reuptake Inhibitors (SSRIs)

6.4 Central Nervous System (CNS) Stimulants

6.5 Tricyclic Antidepressants

6.6 Monoamine Oxidase Inhibitors

6.7 Others

7 Market Breakup by Disorder Type

7.1 Major Depressive Disorder

7.2 Obsessive-Compulsive Disorder

7.3 Generalized Anxiety Disorder

7.4 Panic Disorder

7.5 Others

8 Market Breakup by Drug Type

8.1 Generic Drugs

8.2 Branded Drugs

9 Market Breakup by Distribution Channel

9.1 Hospital Pharmacies

9.2 Retail Pharmacies

9.3 Online Pharmacies

9.4 Others

10 Market Breakup by Region

10.1 North America

10.2 Europe

10.3 Asia Pacific

10.4 Middle East and Africa

10.5 Latin America

11 SWOT Analysis

11.1 Overview

11.2 Strengths

11.3 Weaknesses

11.4 Opportunities

11.5 Threats

12 Value Chain Analysis

13 Porter’s Five Forces Analysis

13.1 Overview

13.2 Bargaining Power of Buyers

13.3 Bargaining Power of Suppliers

13.4 Degree of Competition

13.5 Threat of New Entrants

13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure

15.2 Key Players

15.3 Profiles of Key Players

15.3.1 Otsuka Pharmaceutical

15.3.2 Pfizer

15.3.3 Eli Lilly and Company

15.3.4 AstraZeneca

15.3.5 Novartis

15.3.6 Bristol-Myers Squibb

15.3.7 GlaxoSmithKline

15.3.8 Takeda Pharmaceutical Company

15.3.9 Allergan

15.3.10 Johnson & Johnson

15.3.11 Zhejiang NHU Company Ltd.

15.3.12 Sebela Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/e1wod0

View source version on businesswire.com:https://www.businesswire.com/news/home/20191118005513/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH MENTAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/18/2019 09:43 AM/DISC: 11/18/2019 09:43 AM

http://www.businesswire.com/news/home/20191118005513/en